



PARABOLIC DRUGS LTD.

CIN No. : L24231CH1996PLC017755.

(Under Corporate Insolvency Resolution Process vide Order of Hon'ble NCLT dated 30.08.2018)

Statement of Un-Audited Financial Results for the Quarter & Year ended June 30, 2020

S. No.	Particulars	(Figures In Crores)			
		Quarter Ended			Year Ended
		30-Jun-20	31-Mar-20	30-Jun-19	31-Mar-20
		Un-Audited	Un-Audited	Audited	Un-Audited
I	Income				
	a) Revenue from operations	-	-	-	-
	b) Other Operating Income				
	Total Income from operations (net)	-	-	-	-
II	Other Income			0.01	0.02
III	Total Income (I+II)	-	-	0.01	0.02
IV	Expenses				
	(a) Cost of raw materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expenses	0.42	0.42	1.09	1.68
	(e) Finance Cost	0.17	0.17	0.16	0.66
	(f) Depreciation and amortisation expense	5.34	5.34	5.56	21.59
	(g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	1.29	1.29	0.86	4.73
	Total Expenses	7.22	7.22	7.67	28.66
V	Profit/ (Loss) Before Exceptional and Extraordinary Items and Tax (III-IV)	(7.22)	(7.22)	(7.66)	(28.64)
VI	Exceptional Items	-	-	-	-
VII	Profit/ (Loss) before extraordinary items and Tax (V-VI)	(7.22)	(7.22)	(7.66)	(28.64)
VIII	Extraordinary items	-	-	-	-
IX	Profit before tax (VII- VIII)	(7.22)	(7.22)	(7.66)	(28.64)
X	Tax Expenses				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	0.17	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(7.22)	(7.22)	(7.49)	(28.64)
XII	Net Profit/ (Loss) from discontinuing operation (before Tax)	-	-	-	-
XIII	Tax Expense of discontinuing operations	-	-	-	-
XIV	Net Profit/ (Loss) from discontinuing operation after Tax (XII-XIII)	-	-	-	-
XV	Net Profit/ (Loss) for the Period (XI+XIV)	(7.22)	(7.22)	(7.49)	(28.64)
XVI	Share of profit / (loss) of associates	-	-	-	-
XVII	Share of profit / (loss) of Minority	-	-	-	-
XVIII	Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates	(7.22)	(7.22)	(7.49)	(28.64)
XIX	Other Comprehensive Income	-	-	-	-
XX	Total Comprehensive Income for the period (XVIII+XIX)	(7.22)	(7.22)	(7.49)	(28.64)
XXI	Paid-up share capital (Face value of Rs.10/- per share)	61.89	61.89	61.89	61.89

XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(1,004.26)
XXIII	Earning Per Share (of Rs. 10/- each)				
	A) Basic	(1.17)	(1.17)	(1.21)	(4.63)
	B) Diluted	(1.17)	(1.17)	(1.21)	(4.63)

Notes:

- 1 The Company is undergoing Corporate Insolvency Resolution Process ("CIRP") under the provisions of Insolvency and Bankruptcy Code, 2016, pursuant to order dated August 30, 2018, passed by Hon'ble National Company Law Tribunal (NCLT), Chandigarh Bench. In terms of Section 20 of Insolvency Code, the management and operations of the Company are being managed by Resolution Professional on a Going Concern Basis.
- 2 As the powers of the Board of Directors have been suspended, the above results have not been adopted by the Board of Directors. However, the same have been signed by Resolutional Professional of the Company.
- 3 During the period under review the company has incurred loss mainly owing to depreciation, employee benefit expenses the interest burden and economic stress.
- 4 The promoter's shareholding (22619927 Equity Shares) has been pledged pursuant to the terms of CDR package.
- 5 There is not more than one reportable segment i.e. Pharmaceuticals business only hence information as per Ind AS17 is not required to be disclosed.
- 6 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- 7 During the quarter ended June 30, 2020 most of the lenders have not charged interest due to NPA status of loan accounts. Hence, no provision for interest has been made. We are unable to verify the balances as on 30.06.2020 due to non-availability of balance confirmation from banks.
- 8 The annual employee cost of the company is Rs.4.26 Crs but the employee cost mentioned above pertains to employees for which services has been availed during insolvency proceedings. In view of above, the company may have a contingent liability of Rs.2.58 Crs

For PARABOLIC DRUGS LIMITED

Raj Kumar



Place: Delhi
Date: 20/10/2020

Raj Kumar Ralhan
Resolution Professional of Parabolic Drugs Limited
IP Registration No.: IBB/PA-001/IP-P00981/2017-2018/11614